C
Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
ASX:CYC
Price:
1.665 AUD
-0.3%
Market Closed
Updated:
May 15, 2024
Cyclopharm Ltd
Cost of Revenue
|
Cyclopharm Ltd
Cost of Revenue Peer Comparison
Comparables:
NTI
IPD
COH
OIL
EMV
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cost of Revenue
-AU$10.3m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-11%
|
|
|
Neurotech International Ltd
ASX:NTI
|
Cost of Revenue
AU$870
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ImpediMed Ltd
ASX:IPD
|
Cost of Revenue
-AU$1.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Cochlear Ltd
ASX:COH
|
Cost of Revenue
-AU$527.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cost of Revenue
AU$815.7k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Cyclopharm Ltd's Cost of Revenue?
Cost of Revenue
-10.3m
AUD
-10.3m
AUD
Based on the financial report for Dec 31, 2023, Cyclopharm Ltd's Cost of Revenue amounts to -10.3m AUD.
What is Cyclopharm Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-11%
-11%
Over the last year, the Cost of Revenue growth was -38%. The average annual Cost of Revenue growth rates for Cyclopharm Ltd have been -37% over the past three years , -28% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet
